hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.2478/10004-1254-60-2009-1885

Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

Nada Božina ; Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia
Vlasta Bradamante ; Department of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia
Mila Lovrić ; Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia

Puni tekst: engleski, pdf (168 KB) str. 217-242 preuzimanja: 9.173* citiraj
APA 6th Edition
Božina, N., Bradamante, V. i Lovrić, M. (2009). Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. Arhiv za higijenu rada i toksikologiju, 60 (2), 217-242. https://doi.org/10.2478/10004-1254-60-2009-1885
MLA 8th Edition
Božina, Nada, et al. "Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk." Arhiv za higijenu rada i toksikologiju, vol. 60, br. 2, 2009, str. 217-242. https://doi.org/10.2478/10004-1254-60-2009-1885. Citirano 25.09.2020.
Chicago 17th Edition
Božina, Nada, Vlasta Bradamante i Mila Lovrić. "Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk." Arhiv za higijenu rada i toksikologiju 60, br. 2 (2009): 217-242. https://doi.org/10.2478/10004-1254-60-2009-1885
Harvard
Božina, N., Bradamante, V., i Lovrić, M. (2009). 'Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk', Arhiv za higijenu rada i toksikologiju, 60(2), str. 217-242. https://doi.org/10.2478/10004-1254-60-2009-1885
Vancouver
Božina N, Bradamante V, Lovrić M. Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. Arh Hig Rada Toksikol. [Internet]. 2009 [pristupljeno 25.09.2020.];60(2):217-242. https://doi.org/10.2478/10004-1254-60-2009-1885
IEEE
N. Božina, V. Bradamante i M. Lovrić, "Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk", Arhiv za higijenu rada i toksikologiju, vol.60, br. 2, str. 217-242, 2009. [Online]. https://doi.org/10.2478/10004-1254-60-2009-1885

Sažetak
The polymorphic P450 (CYP) enzyme superfamily is the most important system involved in the biotransformation of many endogenous and exogenous substances including drugs, toxins, and carcinogens. Genotyping for CYP polymorphisms provides important genetic information that help to understand the effects of xenobiotics on human body. For drug metabolism, the most important polymorphisms are those of the genes coding for CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5, which can result in therapeutic failure or severe adverse reactions. Genes coding for CYP1A1, CYP1A2, CYP1B1, and CYP2E1 are among the most responsible for the biotransformation of chemicals, especially for the metabolic activation of pre-carcinogens. There is evidence of association between gene polymorphism and cancer susceptibility. Pathways of carcinogen metabolism are complex, and are mediated by activities of multiple genes, while single genes have a limited impact on cancer risk. Multigenic approach in addition to environmental determinants in large sample studies is crucial for a reliable evaluation of any moderate gene effect. This article brings a review of current knowledge on the relations between the polymorphisms of some CYPs and drug activity/toxicity and cancer risk.

Ključne riječi
cancer risk; cytochrome P450; drug metabolism; genotyping; pharmacogenomics; polymorphic allele; xenobiotics

Hrčak ID: 38412

URI
https://hrcak.srce.hr/38412

[hrvatski]

Posjeta: 10.498 *